Texas 2017 - 85th Regular

Texas House Bill HB3189

Filed
 
Out of House Committee
 
Voted on by Senate
 
Governor Action
 
Bill Becomes Law
 

Caption

Relating to the reporting of and access to information related to court-ordered prescription drug substance abuse treatment; providing a criminal penalty.

Impact

The enactment of HB 3189 introduces significant changes to existing state laws around drug treatment reporting and confidentiality. By formalizing the reporting process, the bill seeks to improve the state's ability to intervene and manage cases of prescription drug abuse, thereby potentially reducing the public health burden associated with such substance use. Furthermore, the introduction of criminal penalties for unauthorized access to the submitted information underscores the importance of confidentiality and protection of sensitive data in the context of substance abuse treatment.

Summary

House Bill 3189 aims to enhance the monitoring and reporting protocols regarding court-ordered substance abuse treatment related to prescription drugs in Texas. The bill mandates that judges who order these treatments for defendants submit identifying information to the Texas State Board of Pharmacy, including the names and dates of birth of the individuals involved, and the specific substances abused. This increased accountability is intended to provide better oversight of treatment programs and to assist authorities in tracking substance abuse trends.

Sentiment

The sentiment surrounding HB 3189 is largely supportive, as it addresses critical concerns about prescription drug abuse in Texas. Legislators and advocates for substance abuse recovery largely view the bill as a proactive step towards increased transparency in treatment programs and better law enforcement cooperation. Nonetheless, there may be concerns about the implications of increased bureaucracy and the costs that could arise from stricter reporting requirements.

Contention

While HB 3189 seeks to streamline the reporting of court-ordered substance abuse treatments, some critics express concerns about the potential for overreach and the impacts on patient confidentiality. There is a delicate balance between public health efforts and personal privacy, and detractors of the bill worry that the mandatory reporting could dissuade individuals from seeking necessary treatment. Ultimately, this legislation brings to light vital discussions about the effectiveness of current drug treatment programs and the necessary safeguards to protect the privacy of individuals struggling with addiction.

Companion Bills

No companion bills found.

Previously Filed As

TX HB2767

Relating to the sharing of controlled substance prescription monitoring information between the Texas State Board of Pharmacy and the Health and Human Services Commission for the state Medicaid program.

TX HB343

Relating to the prescriptive authority of certain psychologists; authorizing a fee.

TX SB2173

Relating to a pilot program for the safe disposal of prescription drugs, including controlled substance prescription drugs.

TX HB1402

Relating to the criminal penalties for certain criminal offenses.

TX SB426

Relating to patient access to prescription drugs for off-label use for COVID-19 treatment.

TX HB1373

Relating to a pilot program for the safe disposal of controlled substance prescription drugs.

TX HB4123

Relating to access to and use of certain criminal history record information.

TX HB972

Relating to warning labels for opioid prescription drugs.

TX HB816

Relating to warning labels for opioid prescription drugs.

TX HB208

Relating to the punishment for certain controlled substance offenses committed in a drug-free zone; increasing criminal penalties.

Similar Bills

CA AB149

Controlled substances: prescriptions.

CA AB1998

Opioids: safe prescribing policy.

CA AB1753

Controlled substances: CURES database.

CA SB1379

Pharmacy: remote services.

TX HB2594

Relating to disposal of controlled substance prescription drugs by hospice service providers.

NJ A380

Requires prescriptions for animals to be issued in name of animal owner; prohibits unnamed persons from possessing prescribed drugs; and requires Prescription Monitoring Program to include information about controlled substances prescribed by veterinarians.

NJ A188

Requires prescriptions for animals to be issued in name of animal owner; prohibits unnamed persons from possessing prescribed drugs; and requires Prescription Monitoring Program to include information about controlled substances prescribed by veterinarians.

NJ S1327

Permits patients to indicate that they should not be prescribed opiates and certain other controlled substances in prescription monitoring program information.